Browse

Randomized phase III trial of irinotecan plus cisplatin versus etoposide plus cisplatin in chemotherapy-naïve Korean patients with extensive-disease small cell lung cancer

Cited 17 time in Web of Science Cited 17 time in Scopus
Authors
Kim, Dong-Wan; Kim, Hoon-Gu; Kim, Joo-Hang; Park, Keunchil; Kim, Hoon-Kyo; Jang, Joung Soon; Kim, Bong-Seog; Kang, Jin-Hyoung; Lee, Kyung Flee; Kim, Sang-We; Ryoo, Hun Mo; Kim, Jin-Soo; Lee, Ki Hyeong; Kwon, Jung Hye; Choi, Jin-Hyuk; Shin, Sang Won; Hahn, Seokyung; Heo, Dae Seog
Issue Date
2019-01
Citation
Cancer Research and Treatment, Vol.51 No.1, pp.119-127
Keywords
EtoposideIrinotecanCisplatinSmall cell lung carcinomaKorean
Abstract
Purpose This randomized phase III study was designed to compare the efficacy and safety of irinotecan plus cisplatin (IP) over etoposide plus cisplatin (EP) in Korean patients with extensive-disease small-cell lung cancer (SCLC). Materials and Methods Patients were randomly assigned to receive IP, composed of irinotecan 65 mg/m(2) intravenously on days 1 and 8+cisplatin 70 mg/m(2) intravenously on day 1 every 3 weeks, or EP, composed of etoposide 100 mg/m(2) intravenously on days 1, 2, 3+cisplatin 70 mg/m(2) intravenously on day 1, every 3 weeks for a maximum of six cycles, until disease progression, or until unacceptable toxicity occurred. The primary endpoint was overall survival. Results A total of 362 patients were randomized to IP (n=173) and EP (n=189) arms. There were no significant differences between IP and EP arms for the median overall survival (10.9 months vs. 10.3 months, p=0.120) and the median progression-free survival (6.5 months vs. 5.8 months, p=0.115). However, there was a significant difference in response rate (62.4% vs. 48.2%, p=0.006). The pre-planned subgroup analyses showed that IP was associated with longer overall survival in male (11.3 months vs. 10.1 months, p=0.036), <65 years old (12.7 months vs. 11.3 months, p=0.024), and Eastern Cooperative Oncology Group performance status 0/1 (12.4 months vs. 10.9 months, p=0.040) patient groups. The severity of treatment-related adverse events such as grade 3/4 anemia, nausea and diarrhea was more frequent in patients treated with IP. Conclusion The IP chemotherapy did not significantly improve the survival compared with EP chemotherapy in Korean patients with extensive-disease SCLC.
ISSN
1598-2998
URI
https://hdl.handle.net/10371/165214
DOI
https://doi.org/10.4143/crt.2018.019
Files in This Item:
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Cancer Research Institute (암연구소)Journal Papers (저널논문_암연구소)
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse